Orlance, Inc. is addressing improving delivery of therapeutic and prophylactic vaccines for a wide range of viral targets. Current vaccines suffer from partial or short-lived effectivity, dosage limitations, poor targeting, side effects, and production constraints. DNA vaccines have aimed to solve these problems but have been limited to date by inadequate delivery systems and formulations. The Orlance team brings a track record of several successful biotechnology advancements and commercialization--coupled with novel University of Washington and National Cancer Institute innovations in gene gun delivery systems, conserved elements expressed in targeted nanoparticle to the urgent problem of enabling DNA vaccines to break through into multiple human disease markets that lack effective preventatives or therapies. Orlance gene gun technology has established proof-of-concept in pre-clinical influenza and HIV/SIV animals models. The company is now addressing optimization of clinical-ready delivery systems and DNA vaccine formulations to bring forward commercial formats for both internal and partner vaccines.
